Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library.
The human immunodeficiency virus (HIV-1) envelope glycoprotein (GP) 120 interacts with CD4 and the CCR5 coreceptor for viral entry. The V3 loop in GP120 is a crucial region for determining coreceptor usage during viral entry, and a variety of amino acid substitutions has been observed in clinical isolates. To construct an HIV-1 V3 loop library, we chose 10 amino acid positions in the V3 loop and incorporated random combinations (27,648 possibilities) of the amino acid substitutions derived from 31 R5 viruses into the V3 loop of HIV-1(JR-FL) proviral DNA. The constructed HIV-1 library contained 6.6 x 10(6) independent clones containing a set of 0-10 amino acid substitutions in the V3 loop. To address whether restricted steric alteration in the V3 loop could confer resistance to an entry inhibitor, TAK-779, we selected entry inhibitor-resistant HIV-1 by increasing the concentration of TAK-779 from 0.10 to 0.30 microM in PM1-CCR5 cells with high expression of CCR5. The selected viruses at passage 8 contained five amino acid substitutions in the V3 loop without any other mutations in GP120 and showed 15-fold resistance compared with the parental virus. These results indicated that a certain structure of the V3 loop containing amino acid substitutions derived from 31 R5 viruses can contribute to the acquisition of resistance to entry inhibitors binding to CCR5. Taken together, this type of HIV-1 V3 loop library is useful for isolating and analyzing the specific biological features of HIV-1 with respect to alterations of the V3 loop structure.
Department of Medical Virology, Graduate School of Medical Sciences, Kumamoto University, 2-1-1 Honjo, Kumamoto 860-8556, Japan. yusak@kaiju.medic.kumamoto-u.ac.jp
Keisuke
K
Yusa
Yosuke
Y
Maeda
Aki
A
Fujioka
Kazuaki
K
Monde
Shinji
S
Harada
D000577:Amides / Q000494:pharmacology*; D000595:Amino Acid Sequence; D001483:Base Sequence; D001665:Binding Sites; D065100:CCR5 Receptor Antagonists; D002460:Cell Line; D004279:DNA, Viral / Q000737:chemistry; D004305:Dose-Response Relationship, Drug; D024882:Drug Resistance, Viral; D015723:Gene Library; D006678:HIV / Q000737:chemistry; D015699:HIV Envelope Protein gp120 / Q000737:chemistry*; D015497:HIV-1 / Q000235:genetics / Q000378:metabolism*; D006367:HeLa Cells; D006801:Humans; D020128:Inhibitory Concentration 50; D008957:Models, Genetic; D008969:Molecular Sequence Data; D009154:Mutation; D010957:Plasmids / Q000378:metabolism; D011110:Polymorphism, Genetic; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D000644:Quaternary Ammonium Compounds / Q000494:pharmacology*; D019713:Receptors, CCR5 / Q000737:chemistry; D011994:Recombinant Proteins / Q000737:chemistry; D012190:Retroviridae / Q000235:genetics; D017386:Sequence Homology, Amino Acid; D012689:Sequence Homology, Nucleic Acid; D013997:Time Factors; D014162:Transfection
D000577:Amides; D065100:CCR5 Receptor Antagonists; D004279:DNA, Viral; D015699:HIV Envelope Protein gp120; D000644:Quaternary Ammonium Compounds; D019713:Receptors, CCR5; D011994:Recombinant Proteins; C119369:TAK 779